The role of vincristine in the treatment of childhood acute leukemia

Myron Karon; Emil J. Freireich; Emil Frei; Robert Taylor; Irving J. Wolman; Isaac Djerassi; Stanley L. Lee; Arthur Sawitsky; Juliet Hananian; Oleg Selawry; David James; Phillip George; Richard B. Patterson; Omer Burgert; Farid I. Haurani; Richard A. Oberfield; C. T. Macy; Barth Hoogstraten; Johannes Blom

doi:10.1002/cpt196673332

The role of vincristine in the treatment of childhood acute leukemia

Myron Karon, Emil J. Freireich, Emil Frei, Robert Taylor, Irving J. Wolman, Isaac Djerassi, Stanley L. Lee, Arthur Sawitsky, Juliet Hananian, Oleg Selawry, David James, Phillip George, Richard B. Patterson, Omer Burgert, Farid I. Haurani, Richard A. Oberfield, C. T. Macy, Barth Hoogstraten, Johannes Blom

Graduate School of Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

In a study of 117 patients under the age of 20 with acute leukemia, vincristine (VCR), at 2 mg. per square meter body surface per week, produced complete remissions in 55 per cent and partial remissions in 15 per cent. The drug also induced second remissions. Patients entering complete remission with VCR were randomly allocated to maintenance therapy with VCR or placebo. The median duration of remission was short: 9 weeks for VCR compared with 6 weeks for placebo. The probability of serious neurological toxicity computed according to the time of exposure to VCR, based on the supposition that VCR was not used for maintenance therapy, indicated that the minimal theoretical risk of toxicity for the highest complete remission rate occurred at 4 weeks (38 per cent remissions with 5 per cent toxicity). At 6 weeks, the corresponding probabilities were 54 and 16 per cent.

Original language	English (US)
Pages (from-to)	332-339
Number of pages	8
Journal	Clinical pharmacology and therapeutics
Volume	7
Issue number	3
DOIs	https://doi.org/10.1002/cpt196673332
State	Published - May 1 1966

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1002/cpt196673332

Cite this

Karon, M., Freireich, E. J., Frei, E., Taylor, R., Wolman, I. J., Djerassi, I., Lee, S. L., Sawitsky, A., Hananian, J., Selawry, O., James, D., George, P., Patterson, R. B., Burgert, O., Haurani, F. I., Oberfield, R. A., Macy, C. T., Hoogstraten, B., & Blom, J. (1966). The role of vincristine in the treatment of childhood acute leukemia. Clinical pharmacology and therapeutics, 7(3), 332-339. https://doi.org/10.1002/cpt196673332

Karon, M, Freireich, EJ, Frei, E, Taylor, R, Wolman, IJ, Djerassi, I, Lee, SL, Sawitsky, A, Hananian, J, Selawry, O, James, D, George, P, Patterson, RB, Burgert, O, Haurani, FI, Oberfield, RA, Macy, CT, Hoogstraten, B & Blom, J 1966, 'The role of vincristine in the treatment of childhood acute leukemia', Clinical pharmacology and therapeutics, vol. 7, no. 3, pp. 332-339. https://doi.org/10.1002/cpt196673332

@article{f75f2ac3cf184e52abe5164ee017bb25,

title = "The role of vincristine in the treatment of childhood acute leukemia",

abstract = "In a study of 117 patients under the age of 20 with acute leukemia, vincristine (VCR), at 2 mg. per square meter body surface per week, produced complete remissions in 55 per cent and partial remissions in 15 per cent. The drug also induced second remissions. Patients entering complete remission with VCR were randomly allocated to maintenance therapy with VCR or placebo. The median duration of remission was short: 9 weeks for VCR compared with 6 weeks for placebo. The probability of serious neurological toxicity computed according to the time of exposure to VCR, based on the supposition that VCR was not used for maintenance therapy, indicated that the minimal theoretical risk of toxicity for the highest complete remission rate occurred at 4 weeks (38 per cent remissions with 5 per cent toxicity). At 6 weeks, the corresponding probabilities were 54 and 16 per cent.",

author = "Myron Karon and Freireich, {Emil J.} and Emil Frei and Robert Taylor and Wolman, {Irving J.} and Isaac Djerassi and Lee, {Stanley L.} and Arthur Sawitsky and Juliet Hananian and Oleg Selawry and David James and Phillip George and Patterson, {Richard B.} and Omer Burgert and Haurani, {Farid I.} and Oberfield, {Richard A.} and Macy, {C. T.} and Barth Hoogstraten and Johannes Blom",

note = "Publisher Copyright: {\textcopyright} 1966 American Society for Clinical Pharmacology and Therapeutics.",

year = "1966",

month = may,

day = "1",

doi = "10.1002/cpt196673332",

language = "English (US)",

volume = "7",

pages = "332--339",

journal = "Clinical pharmacology and therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - The role of vincristine in the treatment of childhood acute leukemia

AU - Karon, Myron

AU - Freireich, Emil J.

AU - Frei, Emil

AU - Taylor, Robert

AU - Wolman, Irving J.

AU - Djerassi, Isaac

AU - Lee, Stanley L.

AU - Sawitsky, Arthur

AU - Hananian, Juliet

AU - Selawry, Oleg

AU - James, David

AU - George, Phillip

AU - Patterson, Richard B.

AU - Burgert, Omer

AU - Haurani, Farid I.

AU - Oberfield, Richard A.

AU - Macy, C. T.

AU - Hoogstraten, Barth

AU - Blom, Johannes

PY - 1966/5/1

Y1 - 1966/5/1

N2 - In a study of 117 patients under the age of 20 with acute leukemia, vincristine (VCR), at 2 mg. per square meter body surface per week, produced complete remissions in 55 per cent and partial remissions in 15 per cent. The drug also induced second remissions. Patients entering complete remission with VCR were randomly allocated to maintenance therapy with VCR or placebo. The median duration of remission was short: 9 weeks for VCR compared with 6 weeks for placebo. The probability of serious neurological toxicity computed according to the time of exposure to VCR, based on the supposition that VCR was not used for maintenance therapy, indicated that the minimal theoretical risk of toxicity for the highest complete remission rate occurred at 4 weeks (38 per cent remissions with 5 per cent toxicity). At 6 weeks, the corresponding probabilities were 54 and 16 per cent.

AB - In a study of 117 patients under the age of 20 with acute leukemia, vincristine (VCR), at 2 mg. per square meter body surface per week, produced complete remissions in 55 per cent and partial remissions in 15 per cent. The drug also induced second remissions. Patients entering complete remission with VCR were randomly allocated to maintenance therapy with VCR or placebo. The median duration of remission was short: 9 weeks for VCR compared with 6 weeks for placebo. The probability of serious neurological toxicity computed according to the time of exposure to VCR, based on the supposition that VCR was not used for maintenance therapy, indicated that the minimal theoretical risk of toxicity for the highest complete remission rate occurred at 4 weeks (38 per cent remissions with 5 per cent toxicity). At 6 weeks, the corresponding probabilities were 54 and 16 per cent.

UR - http://www.scopus.com/inward/record.url?scp=0013910061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0013910061&partnerID=8YFLogxK

U2 - 10.1002/cpt196673332

DO - 10.1002/cpt196673332

M3 - Article

C2 - 5327856

AN - SCOPUS:0013910061

SN - 0009-9236

VL - 7

SP - 332

EP - 339

JO - Clinical pharmacology and therapeutics

JF - Clinical pharmacology and therapeutics

IS - 3

ER -

The role of vincristine in the treatment of childhood acute leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this